

1 **Using Event Related Potentials to Characterise Inhibitory Control and Self-Monitoring**
2 **Across Impulsive and Compulsive Phenotypes: A Dimensional Approach to OCD**

3 Authors: Sakshi Dhir¹, Kaelasha Tyler¹, Lucy Albertella¹, Samuel R. Chamberlain^{2,3}, Wei-
4 Peng Teo^{4,5}, Murat Yücel^{1*}, and Rebecca A. Segrave^{1*}

5 ¹ BrainPark, Turner Institute for Brain and Mental Health, School of Psychological Sciences
6 and Monash Biomedical Imaging Facility, Monash University. Victoria, Australia

7 ² Department of Psychiatry, Faculty of Medicine, University of Southampton, Southampton,
8 UK

9 ³ Southern Health NHS Foundation Trust, Southampton, Hampshire, UK

10 ⁴ Physical Education and Sports Science Academic Group, National Institute of
11 Education, Nanyang Technological University, Jurong West, Singapore

12 ⁵ Institute for Physical Activity and Nutrition, Deakin University, Victoria, Australia

13

14 Submitted 27 March 2022

15 Accepted 28 March 2022

16

17 Corresponding author: Sakshi Dhir; Email: sakshi.dhir@monash.edu

18

19

20

21

22

23

24

25

26

DOI: 10.1017/S109285292200075X

This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article may be cited using its DOI.

27

Abstract

28 **Objective:** ‘Subsyndromal’ Obsessive Compulsive Disorder symptoms (OCDS) are common
29 and cause impaired psychosocial functioning. OCDS are better captured by dimensional
30 models of psychopathology, as opposed to categorical diagnoses. However, such dimensional
31 approaches require a deep understanding of the underlying neurocognitive drivers and
32 impulsive and compulsive traits (i.e., neurocognitive phenotypes) across symptoms. This
33 study investigated inhibitory control and self-monitoring across impulsivity, compulsivity
34 and their interaction in individuals ($n = 40$) experiencing mild-moderate OCDS.

35 **Methods:** EEG recording concurrent with the stop signal task was used to elicit event related
36 potentials (ERPs) indexing inhibitory control (i.e., N2 and P3) and self-monitoring (i.e., ERN
37 and CRN: negativity following erroneous or correct responses, respectively).

38 **Results:** During unsuccessful stopping, individuals high in both impulsivity and compulsivity
39 displayed enhanced N2 amplitude, indicative of conflict between the urge to respond and
40 need to stop ($F(3, 33) = 1.48, p < .05, 95\% \text{ CI} [-.01, .001]$). Individuals high in compulsivity
41 and low in impulsivity showed reduced P3 amplitude, consistent with impairments in
42 monitoring failed inhibitory control ($F(3, 24) = 2.033, p < .05, 95\% \text{ CI} [-.002, .045]$).
43 Following successful stopping, high compulsivity (independent of impulsivity) was
44 associated with lower CRN amplitude, reflecting hypo-monitoring of correct responses ($F(4,$
45 $32) = 4.76, p < .05, 95\% \text{ CI} [.01, .02]$), and with greater OCDS severity ($F(3, 36) = 3.32, p <$
46 $.05, 95\% \text{ CI} [.03, .19]$).

47 **Conclusion:** The current findings provide evidence for differential, ERP indexed inhibitory
48 control and self-monitoring profiles across impulsive and compulsive phenotypes in OCDS.

49

50 **Key words:** Impulsivity, Compulsivity, Phenotyping, N2, P3, ERN, CRN, Inhibitory
51 Control, Self-Monitoring

52

53

54

55

Introduction

56 Ritualistic behaviours (i.e., compulsions) in response to intrusive thoughts and/or images
57 (i.e., obsessions) impact approximately 25% of people at some point in their life¹⁻⁴. These
58 highly prevalent OCD symptoms (OCDS), that is symptoms regardless of whether they meet
59 a diagnostic threshold, are associated with disruptions in psychosocial functioning and
60 psychological distress². For instance, there is compelling evidence from a large data set (n =
61 7076) that people experiencing subsyndromal symptoms and those with OCD, as compared
62 to those with no lifetime experience of obsessive thoughts and compulsive behaviours, show
63 similar impairments in physical health, functioning, psychological vulnerabilities and
64 psychiatric co-morbidities⁵. Further, there is evidence of dimensional OCDS being associated
65 with worsened quality of life across work, relationships and leisure when controlling for
66 other variables⁶. In addition, it has been documented that approximately 1.2% of people who
67 experience OCDS go on to develop Obsessive Compulsive Disorder (OCD), and OCDS are
68 common across other mental illnesses, such as anxiety disorders, and impulse control
69 disorders such as Tourette Syndrome and substance use disorders^{1,2,7}. The categorical
70 diagnostic approach in psychiatric classification systems (DSM-5 and ICD-11), however, do
71 not recognise subsyndromal symptoms⁸. An alternative and increasingly utilised means of
72 understanding 'sub-clinical' psychopathology, such as OCDS, is to take a dimensional
73 approach and investigate the traits and neurocognitive drivers, i.e., neurocognitive
74 phenotypes, that underpin a large breadth of these symptoms^{9,10}. This approach i) enables
75 identification of subsyndromal presentations, and ii) promotes prevention and early
76 intervention approaches targeting underlying drivers, as opposed to attempting treatment only
77 when symptoms are more ingrained and meet diagnostic thresholds.

78 Impulsivity and compulsivity are two interlinked dimensional traits core to OCDS.

79 Impulsivity is a tendency towards strong urges without forethought, often associated with

80 short-term reward¹¹⁻¹³, whereas compulsivity is a tendency towards repetitive behaviours
81 accompanied by the feeling that one ‘has to’ perform them, coupled with an awareness that
82 they are incongruent with overall goals¹⁴. Whilst both traits result in the common outcome of
83 dyscontrol over behaviour, they are classically held to be driven by differing underlying
84 motivations: impulsivity by an urge to obtain reward and compulsivity by the desire to avoid
85 harm, fear of uncertainty and/or habit¹⁵⁻²⁰. Traditionally impulsivity and compulsivity were
86 considered to be orthogonally opposed, however recent evidence show a more complex
87 interdependent relationship where, particularly at the extreme ends, they interact in a way that
88 is reflected in specific clinical outcomes²¹⁻²³. These different loadings of impulsivity and
89 compulsivity are reflected as distinct phenotypes. People high in both traits have shown more
90 chronic²⁴ and severe OCDS²⁵ with poorer prognosis²⁶. Thus, characterising the overlapping
91 and distinct underlying drivers of impulsivity, compulsivity and their interaction in OCDS
92 may uncover particularly ‘at risk’ individuals, facilitating intervention before symptoms
93 escalate.

94 Two key neurocognitive drivers of impulsivity and compulsivity that may hold the
95 key to better understanding OCDS are inhibitory dyscontrol and impaired self-monitoring.
96 Inhibitory dyscontrol refers to the inability to withhold a response, such as difficulty resisting
97 compulsive urges to wash hands, and is common to both impulsivity and compulsivity²⁷⁻³¹.
98 Hyperactivity self-monitoring, which has been robustly implicated in high compulsivity^{27,32-}
99 ³⁴, involves persistent observing, checking and questioning ‘correct’ performance, which is
100 often described as the feeling of something being ‘not just right’. This doubt about
101 performance being ‘correct’, for example doubt that hands are clean, triggers a compensatory
102 system in the form of compulsive behaviours such as excessive handwashing. On the other
103 hand, hypoactive self-monitoring has been shown, albeit with limited evidence, in high
104 impulsivity³⁵. Such nuanced commonalities in inhibitory control and differences in self-

105 monitoring between compulsivity and impulsivity may distinctly drive OCDS. For example,
106 a person with high impulsivity could be characterised by impaired inhibitory control and
107 hypoactive self-monitoring, and as such experience strong impulses to engage in repetitive
108 handwashing. Whereas a person with high compulsivity could experience the same
109 handwashing behaviour, but be driven by impaired inhibitory control and hyperactive self-
110 monitoring, and associated doubt about the cleanliness of their hands ³⁶. Thus, characterising
111 inhibitory control and self-monitoring across impulsive and compulsive phenotypes may
112 identify the unique individual's drivers of OCDS.

113 Event related potentials (ERPs) are time-locked electrophysiological brain responses
114 elicited in direct response to sensory, cognitive, or motor events. A number of ERPs have
115 been directly linked to specific neurocognitive aspects of inhibitory control and self-
116 monitoring. Inhibitory control is strongly associated with the N2 (a negative ERP deflection
117 approximately 200ms after encountering a cue to 'stop' a response), with a greater N2
118 amplitude thought to reflect the strength of one's preconscious recognition of the need to stop
119 ^{37,38}. There is also a large body of evidence indicating that the latency of the P3 (a positive
120 ERP deflection approximately 300ms after the stop signal) is a sensitive index of the onset of
121 the inhibition process ³⁹ and the amplitude reflects the magnitude of the inhibition response
122 ⁴⁰⁻⁴². Moreover, the strength of self-monitoring has been strongly associated with the
123 magnitude of Error-Related Negativity (ERN) and Correct-Related Negativity (CRN)
124 (negative deflections 100ms after failed (i.e., 'an error') or successful inhibition,
125 respectively)³³ (Figure 1). Thus, these ERPs provide a highly sensitive means of investigating
126 the common and distinct neurophysiological mechanisms of inhibitory control and self-
127 monitoring across impulsivity and compulsivity, and as such uncovering the neurocognitive
128 phenotypes across OCDS.

129

130 **Figure 1:** Schematic Representation of N2, P3 and ERN/CRN during The Stop Signal Task
131

132 The evidence for N2/P3 and ERN/CRN across impulsivity and compulsivity is sparse.
133 There is evidence⁴³ of an enhanced N2 amplitude in OCD, an archetypal compulsive
134 condition, compared to gambling disorder, an archetypal impulsive condition. The authors
135 positioned the early inhibitory control process, indexed by the N2, as a candidate *differential*
136 phenotype for compulsivity as compared to impulsivity. Additionally, a comprehensive
137 systematic review⁴⁴ of ERPs associated with OCD provided evidence of enhanced ERN, and
138 associated hyperactive self-monitoring, as an endophenotype for OCD. These finding
139 highlighted the utility of ERPs for neurocognitively phenotyping OCDS. However, the scant
140 research that has been conducted in this area has focused exclusively on inhibitory control
141 and self-monitoring related ERPs in OCD, rather than investigating whether they are
142 sensitive markers of impulsivity and compulsivity dimensionally. Thus, the extent to which
143 inhibitory control, indexed by N2/P3, and self-monitoring, indexed by ERN/CRN, are makers
144 across impulsivity and compulsivity in OCDS remains unknown.

145 In sum, impulsivity and compulsivity play an important, complex, differential, and
146 only partially understood role in driving OCDS. The identification of impulsive and
147 compulsive neurocognitive phenotypes across OCDS would contribute to early detection and
148 targeted early intervention efforts. Impairments in inhibitory control and self-monitoring are
149 central to impulsivity and compulsivity and can be sensitively indexed via ERPs. Thus, the
150 current study attempted to neurocognitively phenotype impulsivity and compulsivity in
151 OCDS by investigating the extent to which impulsivity, compulsivity, and their interactions
152 were associated with impairments in inhibitory control indexed by N2 and P3, and self-
153 monitoring indexed by ERN and CRN, in people with mild to moderate OCDS. It was
154 hypothesised that greater compulsivity would be associated with hyper self-monitoring,
155 reflected by enhanced ERN/CRN, and greater impulsivity with hypo self-monitoring,

156 reflected by reduced ERN/CRN. Additionally, it was hypothesised that high impulsivity and
157 compulsivity would both be associated with a range of inhibitory control impairments,
158 reflected by altered N2 and P3.

159

160

Method

161 **Participants**

162 Forty right-handed adults (female = 33, male = 7; $M \pm SD$ years = 24.25 ± 5.20) experiencing
163 mild ($n = 16$) to moderate ($n = 24$) OCDS took part in the study, with mild severity defined
164 by scores between 8-15 and moderate by scores between 16-23 on the Yale Brown Obsessive
165 Compulsive Scale-Revised (YBOCS-R)⁴⁵. All participants had normal or corrected-to-
166 normal vision and met the exclusion criteria of no lifetime history of DSM-5 defined
167 psychotic illness, Bipolar Affective Disorder, Bulimia or Anorexia Nervosa, Substance Use
168 or Gambling Disorder, neurological illness or moderate - severe brain injury and stimulant
169 medication use. Participants were recruited through social media, posters placed around the
170 community, and an anxiety and OCD helpline. The study received approval from the Monash
171 University Human Ethics Committee and all participants provided informed consent.
172 Participants were paid \$40 to compensate for their time and effort.

173

174 **Procedure**

175 Data were collected during a single experimental session conducted at the Monash
176 Biomedical Imaging Centre and BrainPark, Melbourne. The experimental protocol began
177 with a clinical interview and questionnaires to collect demographic, diagnostic and
178 psychological data. All participants completed the Stop Signal Task (SST) with concurrent
179 EEG recording. All clinical interviews, questionnaires and cognitive tasks were administered

180 by a single researcher who was a provisional psychologist and trained in their standardised
181 administration. See Supplementary Material Section A for a detailed outline of all measures.

182

183 **Interviews**

184 OCDS severity was assessed by the Yale Brown Obsessive Compulsive Scale-Revised
185 (YBOCS-R)⁴⁵. The YBOCS-R is a gold-standard frequently utilised measure of obsession
186 and compulsion symptom severity¹⁰.

187 Exclusion criteria was assessed by the Mini-International Neuropsychiatric Interview
188 (MINI)⁴⁶. The MINI is a diagnostic research tool used to assess whether a person meets
189 criteria for current or past common DSM-IV defined mental illnesses.

190

191 **Questionnaires**

192 The use of the following self-report questionnaires to capture dimensional impulsivity and
193 compulsivity has been applied across a range of prior studies, and reliably differentiates
194 between the two traits⁴⁷⁻⁴⁹. Compulsivity was assessed by the composite total score of The
195 Obsessional Beliefs Questionnaire⁵⁰ a 44-item scale used to measure the level of obsessional
196 beliefs, and The Intolerance of Uncertainty Scale⁵¹, a 12-item scale used to assess responses
197 to uncertain and ambiguous possibilities, including the future. Impulsivity was assessed by
198 the total score on the short version of the Urgency, Premeditation, Perseverance, Sensation
199 Seeking and Positive Urgency, Impulsive Behaviour (UPPS-P), a 59 item scale used to
200 measure domains of impulsivity⁵².

201 The Warwick Edinburgh Mental Well-being Scale (WEMWBS)⁵³, a 14-item scale,
202 was used to measure overall wellbeing and psychological functioning. Higher scores indicate
203 a higher level of wellbeing. The WEMWBS shows high levels of internal consistency,

204 reliability and usefulness at a population-level. A WEMWM score <40 has been found across
205 populations accessing secondary care mental health services⁵⁴.

206

207 **Stop Signal Task**

208 Inhibitory control was assessed using a gold-standard version of the Stop-Signal task (SST)
209 which had been shown to sensitively elicit inhibitory control related ERPs^{39,55}. The SST was
210 run via MATLAB (version 2019b). A fixation cross was presented on the monitor screen for
211 500ms, followed by the target 'Go' stimuli indicated by a white arrow, which required a
212 response with the corresponding left/right computer key (response deadline/presentation:
213 1000ms). On 33% of the trials, the 'Go' stimuli was followed by the 'Stop' stimuli, indicated
214 by a red arrow (presented for 100m), which required participants to withhold their response.
215 The longer the stop signal delay (SSD; the time between the 'Go' and 'Stop' stimuli), the more
216 difficult it is for participants to successful stop a response. The SSD was adjusted by 50ms
217 increments (starting at 200ms) to ensure adaptive difficulty and an accuracy rate of 50% for all
218 participants. The behavioural metric collected was the Stop Signal Reaction Time (SSRT),
219 which is the time required for a person to stop a response. The SSRT was calculated based on
220 the integration method⁵⁶.

221 Participants completed a total of 240 trials presented in two equal blocks with a short
222 break between blocks. Prior to beginning the task, participants completed a practice trial. The
223 instructions for the task were standardised across all participants ("respond as fast as
224 possible, whilst trying to maintain accuracy"), and a researcher was present throughout task
225 completion to monitor engagement. If participants were observed to strategically slow
226 responses, they were instructed to "remember to respond as fast as possible".

227

228 **Electrophysiological Recording and Pre-Processing**

229 EEG was recorded in a darkened and electrically shielded room using a digital Active-Two
230 system (BioSemi, Amsterdam, Netherlands). Silver chloride (Ag/AgCl) active electrodes
231 were placed at 10 scalp sites (*F3, Fz, F4, C3, Cz, C4, P3, Pz, P4, AFz*) according to the
232 international 10-20 montage system. Four facial electrodes were positioned adjacent to the
233 left and right outer canthus of each eye and above and below the left orbit to measure eye
234 movement. EEG data were referenced to mastoid channels and impedances were kept below
235 5KOhms. Key presses were detected using a regular PC keyboard, which fed triggers to the
236 Active-Two system via the PC serial port. All signals were digitized with a sampling rate of
237 1000 Hz, a 24-bit A/D conversion and a low pass filter of 134.

238 Offline data were processed with EEG LAB open-source toolbox⁵⁷. EEG data were re-
239 referenced to a common average and the mastoid channels removed from further analysis. Data
240 were down sampled to 500 Hz and further filtered using a linear basic FIR filter with a high
241 edge of the frequency band pass of 40 Hz and a low edge of the frequency band pass of 1 Hz.
242 The data were then epoched from 500 ms prior to a Go stimulus to 1500 ms after the Go
243 stimulus. Epochs containing motion artefact were removed. The EEG data set for each
244 participant was then subject to a temporal Independent Component Analysis (ICA)
245 decomposition using the runica infomax algorithm. Based on visual inspection, any
246 components relating clearly to electro-oculogram (EOG) or eye blink artifacts were excluded.
247 EOG channels were then removed from further analysis.

248 All baseline means (i.e., the average microvolt value from -100 ms to 0 ms relative to
249 the Go signal) were removed across trials. Responses made within 50ms of all stimuli
250 presentations were considered as early responses and omitted from analysis. Trials were
251 grouped into: (1) Successful stop trials (trials where participants did not respond after the ‘stop
252 signal’), (2) Failed stop trials (trials where participants incorrectly responded after the ‘stop
253 signal’) and (3) Go trials (trials where participants were not required to inhibit a response).

254 Stop trials with SSDs < 50ms were excluded to safeguard the adaptive difficulty process. Go
255 and stop trials were matched based on SSD to ensure homogenous parameters for comparison
256 of ERPs. Data were re-epoched at -100ms to 500 ms relative to stop signal onset. Latency or
257 amplitude values for P3, N2, ERN and CRN were calculated at the fronto-central EEG channels
258 Cz and Fz. However, consistent with the literature, P3 values reported were those calculated at
259 Fz, and N2, ERN and CRN values reported were those calculated at Cz^{39,58-60}.

260

261 **EEG: Inhibitory Control ERP Calculation**

262 N2 and P3 ERPs were used to index underlying inhibitory control processes. The N2
263 amplitude was defined as the most negative value within the 200–300ms interval post-
264 stimulus onset, and the P3 amplitude as the most positive value within the 300–500ms
265 interval. A modified version of the COMPASS algorithm³⁹ was used to increase signal to
266 noise ratio of N2 and P3 waveforms and to remove ICA derived components which did not
267 represent the N2 and P3 from the analysis (see Supplementary Material Section B). This
268 allowed selection only of those ICA derived components that represented the N2 across
269 successful ($n=37$) and failed ($n=37$) stop trials. Similarly, components were selected that
270 represented P3 onsets within successful ($n=28$) and failed ($n=30$) stop trials, and P3
271 amplitudes across successful ($n=28$) and failed ($n=28$) stop trials.

272

273 **EEG: Self-Monitoring ERP Calculation**

274 ERN and CRN were used to index underlying self-monitoring. ERN was defined as the
275 average peak (μV) from 0-100ms after failed stop trials, and Correct-Related Negativity
276 (CRN), as the average peak (μV) after successful stop trials. Pre-processed data were re-
277 epoched from -400 ms to 800 ms around participant responses. Baseline means (i.e., the
278 average microvolt value) were calculated from 400ms to 200ms prior to participant response.

279 The baseline averages were then removed all across trials⁶¹. This allowed the selection only
280 of components representing ERN ($n = 37$) and CRN ($n = 37$).

281

282 **Statistical Analysis**

283 All statistical analyses were conducted on SPSS and PROCESS. Outliers ($n = 5$ across ERP
284 data) were winsorised (based on Z scores > 3.29). Firstly, to determine differences associated
285 with successful/failed inhibitory control outcomes, independent sample tests were used to
286 analyse group differences between (1) successful and failed stop trials across N2 amplitude
287 and P3 onset and amplitude and (2) ERN and CRN. Then, bootstrapped linear regressions
288 examined whether impulsivity, compulsivity, or their interaction were associated with (1)
289 cognitive inhibitory control outcomes (SSRTs), (2) symptom severity (YBOCS scores), and
290 (3) ERP indices of inhibitory control (N2 Amplitude, P3 Onset, and P3 Amplitude) and self-
291 monitoring (ERN and CRN) across failed and successful stop trials. Impulsivity and
292 compulsivity scores were mean centred according to the respective outcome group, and
293 interaction terms were calculated accordingly to avoid multicollinearity. The unstandardised
294 beta (B) has been reported for all significant ($p < .05$) main effects, i.e., the amount of change
295 in the outcome associated with every unit change in the predictor. Interaction effects were
296 valid given that the independent variables (impulsivity and compulsivity, as operationalised
297 above) were not correlated ($p = .77$). Significant interaction effects were followed up by (1)
298 splitting the groups by impulsivity, and then within each group conducting correlations
299 between compulsivity and the outcome measure and (2) assessing scatterplots to facilitate
300 interpretation⁶². Age, gender and anxiety were controlled in the model when they
301 significantly correlated with the dependent variables, which was only evident for age and
302 CRN.

303

304

Results**305 Participant Characteristics**

306 Participants ($n = 40$) were all within the mild (YBOCS-R score = 8 - 15) to moderate
307 (YBOCS-R score = 16 – 23) range of OCDS. The MINI clinical interview and DSM-5
308 criteria indicated that 15 participants met criteria for OCD, and 25 were experiencing
309 subclinical OCDS. The WEMWBS wellbeing scores were low for participants with mild and
310 moderate symptoms, as compared to norms for healthy young adults⁵³ and were comparable
311 to the norms for people accessing secondary care mental health services⁵⁴ (see Table 1).
312 Participants showed longer SSRTs than the normative mean for healthy young people⁶³,
313 showed more delay P3 onset latencies than previously found using the same SST³⁹ and
314 showed more negative ERN and CRNs compared to the normative data recorded at Cz⁶¹ (see
315 Table 1).

316

317 **Table 1:** Participant Characteristics Across Variables and Normative Data for SSRT, P3
318 Onset, ERN/CRN and Well-Being

319

320

321 OCDS Severity and Stop Signal Reaction Time**322 OCDS Severity**

323 Collectively, impulsivity, compulsivity, their interaction accounted for 46.5% of variance in
324 YBOCS scores ($R^2 = .465$). Higher compulsivity was associated with significantly greater
325 YBOCS scores, ($F(3, 36) = 3.32, p < .05, 95\% \text{ CI } [.03, .19]$), such that for every unit
326 increase in compulsivity, YBOCS scores increased by .09 units ($B = 0.09 (SE = .03)$). Neither
327 impulsivity or the interaction between impulsivity and compulsivity were associated with
328 variation in YBOCS scores (p 's $> .31$).

329 Stop Signal Reaction Time

330 Impulsivity, compulsivity, and their interaction were not associated with significant variation
331 in SSRT ($F(3, 36) = 1.998, p = .13$).

332

333 **Successful versus Failed Stopping Across all ERPs**

334 Consistent with the prior research using the same version of the SST³⁹, latency of the P3
335 onset was significantly earlier during successful as compared to failed stop trials ($t(54) =$
336 $7.68, p < .001, 95\% \text{ CI } [77.26, 131.84]$) (Figure 2, b). There were no significant differences
337 between successful and failed stop trials in N2 or P3 amplitudes ($t(71) = -.48, p = .63, t(54)$
338 $= -0.26, p = .79$, respectively). There were no significant differences in negativity between
339 CRN and ERN ($t(71) = .49, p = .63$) (Figure 3).

340

341 **Figure 2:** Grand Average of The N2 from the Cz Electrode and The P3 from the Fz Electrode

342

343 **Figure 3:** Grand Average of The ERN and CRN from the Cz Electrode

344

345 **Inhibitory Control**

346 *N2 Amplitude*

347 For failed stop trials, the combination of impulsivity, compulsivity and their interaction
348 accounted for 12% of variance in N2 amplitude ($R^2 = .12$). The interaction between
349 impulsivity and compulsivity was associated with significant variation in N2 amplitude ($F(3,$
350 $33) = 1.48, p < .05, 95\% \text{ CI } [-.013, .001], B = .007 (SE = .003)$). No significant correlation
351 was found between compulsivity and N2 amplitude for high and low impulsivity groups ($r =$
352 $-.16, p = .56; r = .11, p = .63$, respectively). Visual depiction of scatterplot data (Figure 4)
353 indicated that the significant interaction effect was driven by a positive relationship between
354 compulsivity and N2 amplitude amongst individuals with low impulsivity, and a negative

355 relationship between compulsivity and N2 amplitude amongst individuals with high
356 impulsivity.

357 For successful stop trials, impulsivity, compulsivity, and their interaction were not
358 associated with significant variation in N2 amplitude ($F(3, 33) = 1.11, p = .36$).

359

360 **Figure 4:** N2 Amplitude During Failed Stop Trials as a Function of Compulsivity Across
361 Low and High Impulsivity

362

363 ***P3 Onset***

364 For successful stop trials, the combination of impulsivity, compulsivity and their interaction
365 accounted for 23% of variance in P3 onset ($R^2 = .23$). Impulsivity was associated with a
366 trend level relationship with greater P3 onset latency ($F(3, 24) = 2.33, p = .099$), such that
367 for every unit increase in impulsivity, P3 onset latency increased by 6.84 units ($B = 6.84$ (SE
368 $= 5.81$) (Figure 5). Compulsivity and the interaction between impulsivity and compulsivity
369 were not associated with significant variation in P3 onset latency (p 's $< .28$)

370 For failed stop trials, impulsivity, compulsivity, and their interaction were not
371 associated with significant variation in P3 onset latency ($F(3, 26) = 1.11, p = .36$).

372

373

374 **Figure 5:** P3 Onset During Successful Stop Trials as a Function of Impulsivity

375

376

377 ***P3 Amplitude***

378 For failed stop trials, the combination of impulsivity, compulsivity and their interaction
379 accounted for 20% of variance in P3 amplitude ($R^2 = .20$). The interaction between
380 impulsivity and compulsivity was associated with significant variation in P3 amplitude ($F(3,$
381 $24) = 2.03, p < .05, 95\% \text{ CI } [-.002, .045], B = .019$ ($SE = .01$)). No significant correlation was
382 found between compulsivity and P3 amplitude in high impulsivity ($r = -.27, p = .40$),

383 however there was a significant correlation between compulsivity and P3 amplitude in low
384 impulsivity ($r = -.54, p < .05$). Visual depiction of scatterplot data (Figure 6) indicated that
385 the significant interaction effect was driven by a positive relationship between P3 amplitude
386 and compulsivity amongst individuals with low levels of impulsivity.

387 For successful stop trials, impulsivity, compulsivity, and their interaction were not
388 associated with significant variation in P3 Amplitude ($F(3, 24) = .50, p = .69$).

389

390 **Figure 6:** P3 Amplitude During Failed Stop Trials as a Function of Compulsivity Across
391 Low and High Impulsivity

392

393 **Self-Monitoring**

394 **ERN**

395 Impulsivity, compulsivity, and their interaction were not associated with significant variation
396 in ERN ($F(3, 33) = .63, p = .60$).

397 **CRN**

398 The combination of impulsivity, compulsivity and their interaction accounted for 37% of
399 variance in CRN ($R^2 = .37$). Compulsivity was associated with larger CRN when controlling
400 for age ($F(4, 32) = 4.76, p < .05, 95\% \text{ CI } [.01, .02]$), such that for every unit increase in
401 compulsivity, CRN increased by .02 units ($B = .02 (SE = .01)$) (Figure 7). Impulsivity and the
402 interaction between impulsivity and compulsivity were not associated with significant
403 variation in CRN ($p = .65, p = .54$)

404

405 **Figure 7:** CRN as a Function of Compulsivity

406

407

Discussion

408 This was the first study to investigate whether varying traits of impulsivity and compulsivity
409 across OCDS could be differentiated by inhibitory control and self-monitoring, as indexed by
410 ERPs. The results indicated that ERPs indexing inhibitory control and self-monitoring did
411 differentiate between impulsive and compulsive phenotypes in OCDS and can contribute to
412 our understanding of the neurocognitive drivers of these traits and symptoms. In particular,
413 when impulsivity was high and compulsivity low, failed inhibitory control was associated
414 with enhanced N2 amplitude, reflecting high conflicts when trying to stop a behaviour.
415 Further, as compulsivity increased, symptom severity also increased and CRN decreased,
416 indicating reduced monitoring of successful inhibitory control. Taken together, two distinct
417 phenotypes, i) high impulsivity/compulsivity and ii) high compulsivity, were identified and
418 their unique neurocognitive profiles were characterised, i) poor inhibitory control (enhanced
419 N2 amplitude) and ii) impaired self-monitoring (reduced CRN), respectively.

420 The finding that high impulsivity and compulsivity were associated with enhanced N2
421 amplitude is consistent with recent evidence⁶⁴ implicating a disrupted N2 amplitude as a
422 marker of an OCD-specific frontal cortical dysfunction that subserves impaired inhibitory
423 control. The current findings extend this evidence by identifying an enhanced N2 amplitude
424 in individuals high in impulsivity and compulsivity at the milder earlier stages in OCDS
425 progression, as most people in this study do not yet meet an OCD diagnosis. Source
426 localisation techniques have associated the N2 amplitude with prefrontal networks^{65,66},
427 including the IFG⁶⁷, which drive inhibitory control^{29,68,69}. In line with this, evidence has
428 positioned N2 amplitude to reflect the conflict between the need to stop and the response
429 urge^{38,70}. Thus, people high in both impulsivity and compulsivity may experience higher
430 conflicts, i.e., enhanced N2 amplitude, between recognising the need to stop unhelpful
431 compulsive behaviours (e.g., awareness of excessive handwashing) and succumbing to urges
432 (e.g., continuing to wash hands). These individuals, high in both impulsivity/ compulsivity,

433 show greater OCD severity²⁵ and chronicity²⁴, higher risk for developing clinically elevated
434 impulse control and compulsive disorders⁷¹, and poorer prognosis²⁶. Thus, the identification
435 of specific inhibitory control impairments, reflected by an enhanced N2 amplitude, in those
436 with high impulsivity and compulsivity could form the basis for the early detection of people
437 that meet this high-risk phenotype, and guide the development of early interventions that are
438 tailored to specifically modulate inhibitory dyscontrol.

439 Impairments across self-monitoring were associated with high compulsivity. The
440 findings that indicated this were i) a greater monitoring of failed stopping (enhanced ERN)
441 across all individuals with OCDS, as compared to healthy norms ii) high compulsivity,
442 independent of impulsivity, associated with lower monitoring of correct performance (lower
443 CRN), and iii) high compulsivity, but low impulsivity, associated with poorer evaluation of
444 failed performance (reduced P3 amplitude during failed stopping)^{58,60,72-75}. Of note, the P3
445 amplitude specifically during failed stopping on the SST^{58,60,72} (not successful stopping) has
446 not shown robust and consistent evidence for indexing either inhibitory control or self-
447 monitoring performance, and thereby CRN will be used as the stronger index of impaired
448 self-monitoring. These findings are consistent with robust evidence that has implicated
449 impaired self-monitoring in OCD via ERN/ERN findings^{33,44} and disruptions across anterior
450 cingulate cortex (ACC) activity^{76,77}. Most of the prior studies have been conducted on
451 individuals diagnosed with OCD and have found error-related alternations^{33,44}. This study
452 provides further evidence of hypo-monitoring of correct performance and greater symptoms
453 severity in highly compulsive people experiencing mild to moderate OCDS, which is earlier
454 in symptom progression than those included in prior clinical studies. In highly compulsive
455 individuals, hypo monitoring of correct performance, indexed by decreased CRN (e.g.,
456 difficulty recognising that hands are sufficiently clean), combined with hyper monitoring of
457 errors indexed by enhanced ERN (e.g., excessively feeling that handwashing is incorrect),

458 may reinforce compensatory, compulsive behaviours (e.g., inability to feel that handwashing
459 is complete)^{32,33,78}. This further neurocognitively characterises (impaired self-monitoring)
460 specific phenotypes (high compulsivity) at the milder end of the OCDS severity continuum.

461 Consistent with literature^{28,69,79}, high impulsivity was associated with a non-
462 significant trend towards a delayed inhibitory control process, indexed by delayed P3 onset³⁹.
463 Taken together, those high in impulsivity may experience an additional, earlier slowing of the
464 inhibitory control process. In other words, impulsive individuals may find it difficult to delay
465 or stop behavioural urges, such as resisting compulsive handwashing, from the onset of the
466 urge.

467 Neurocognitive phenotyping of impulsivity and compulsivity in OCDS could allow
468 at-risk people to be identified earlier for specific interventions that target the drivers of
469 symptoms. More specifically, most participants in the current study did not meet a diagnosis
470 of OCD and were at the early stages of symptom progression (mild-moderate OCDS). Thus,
471 the aforementioned findings collectively characterise the neurocognitive and mechanisms at
472 the lower end of the dimensional spectrum of OCDS, where people are likely in the early ‘at-
473 risk’ stages. This is the first step in enabling early detection of people that may be susceptible
474 to OCD based on their neurocognitive and trait profile. Ultimately, this could enable the
475 development of preventative or early treatments that specifically target the underlying
476 mechanisms of a person's symptoms. These tailored early interventions could, for instance,
477 utilise the knowledge from neurocognitive phenotyping to specifically modulate impairments
478 in self-monitoring in people that fit the high compulsivity phenotype, or modulate
479 impairments across inhibitory control in people that fit the high impulsivity/compulsivity
480 phenotype. This evidence directly informs the ‘phenotype-to-treatment’ approach proposed
481 by Yücel, Lee, Fontenelle²⁷ and is aligned with frameworks proposing the use of
482 interventions to treat underlying drivers of symptoms, such as neurocognitive impairments, as

483 opposed to categorical disorders ^{24,29,36}. Whilst investigations into interventions for targeting
484 inhibitory control are growing ⁸⁰, these are not yet established, and there has been minimal
485 focus on remediating disordered self-monitoring. Thus, future investigations of interventions
486 for subclinical OCDS will benefit from targeting the associated neurocognitive mechanisms
487 (i.e., inhibitory control and self-monitoring) across impulsive and compulsive phenotypes to
488 effectively remediate the underlying drivers of symptoms.

489 The current findings should be considered in light of a number of limitations. Firstly,
490 the focus on mild to moderate severities means that the findings cannot be generalised to
491 more severe OCD presentations. This is important to address in future research as these
492 individuals are likely to be most in demand for earlier assessment and prevention, or more
493 rigorous treatment. The sample is also disproportionately biased towards women. In order to
494 be able to generalise the findings to broader populations, this study should be replicated in
495 larger and more gender balanced samples. Additionally, the lack of a healthy control group as
496 a comparator makes it difficult to disentangle whether the neurocognitive phenotypes were
497 OCDS-specific and not reflective of normative traits within healthy populations. Finally, the
498 results reported from the split group follow up approach, particularly the trend-level result for
499 P3 onset, were based on small sample sizes. Thus, the study would benefit from replication
500 with greater sample sizes.

501 Another important consideration is that, similar to findings by Wessel, Aron ³⁹, P3
502 onset was a more robust marker of successful inhibitory control than N2 and P3 amplitudes.
503 More specifically, it was the only ERP that differentiated between successful versus
504 unsuccessful inhibitory control during the SST. It is possible that this was a result of the same
505 task used in this study and Wessel, Aron ³⁹, as ERPs are sensitive to task metrics ^{37,81,82}.
506 Additionally, given that the P3 amplitude is proposed to be an indicator of the magnitude of
507 the (successful or failed) inhibition response, it may have captured the motor inhibition

508 response (clicking the key or withholding) regardless of stopping success^{83,84}. Further, the P3
509 amplitude, particularly during failed stopping, lacks specificity and has been proposed to also
510 influence attentional processes^{37,85,86}. Thus, the evidence currently implicates the P3 onset as
511 a more consistent indicator of successful inhibitory control, as compared to the N2 and P3
512 amplitudes.

513

514

Conclusion

515 The current study found distinct inhibitory control and self-monitoring profiles, indexed by
516 ERPs, across impulsive and compulsive phenotypes in individuals with mild to moderate
517 OCDS. Firstly, those high in both impulsivity and compulsivity showed greater conflicts
518 when stopping a response during failed inhibitory control, indexed by enhanced N2
519 amplitude. Secondly, those high in only compulsivity showed impairments in self-monitoring
520 that had not yet been documented in the literature, reflect by a reduced CRN, and showed
521 worsened symptom severity. These findings support the use of ERPs for identifying
522 neurocognitive phenotypes across OCDS. This could inform a dimensional approach to
523 characterising OCDS and its underlying mechanisms, that extends beyond binary diagnostic
524 labels. Ultimately, mechanistic-based dimensional frameworks can enable earlier detection,
525 and thereby, allow for early interventions that target the underlying neurocognitive
526 mechanisms of distinct phenotypes across OCDS.

527

528

529

Acknowledgements

530 The authors would like to acknowledge Associate Professor Jan Wessel and Professor Adam
531 Aron for sharing their valuable version of the SST.

532

533

Disclosures

534 SRC receives an honorarium for editorial work at Elsevier. He previously consulted for
535 Promentis. This research was funded in whole, or in part, by Wellcome [110049/Z/15/Z &
536 110049/Z/15/A]. For the purpose of open access, the author has applied a CC BY public
537 copyright licence to any Author Accepted Manuscript version arising from this submission.
538 MY has received funding from Monash University, and Australian Government funding
539 bodies such as the National Health and Medical Research Council (NHMRC; including
540 Fellowship #APP1117188), the Australian Research Council (ARC), Australian Defence
541 Science and Technology (DST), and the Department of Industry, Innovation and Science
542 (DIIS). He has also received philanthropic donations from the David Winston Turner
543 Endowment Fund, Wilson Foundation, as well as payments in relation to court-, expert
544 witness-, and/or expert review-reports. RAS is funded by the David Winston Turner
545 Endowment Fund and has received funding from Monash University, NHMRC, the Wilson
546 Foundation, and not-for-profit bodies such as Beyond Blue, nib Foundation and the Sir
547 Edward Dunlop Medical Research Foundation. The funding sources had no role in the
548 design, management, data analysis, presentation, or interpretation and write-up of the data.

Conflicts of interest

550 The authors declare that there are no conflicts of interest.

Funding

552 This research was supported by an Australian Government Research Training Program
553 Scholarship, the David Winston Turner Endowment Fund and the Wilson Foundation. SRC's
554 role in this research was supported by a Wellcome Clinical Fellowship (110049/Z/15/A &
555 110049/Z/15/Z).

556

References

- 558 1. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-
559 compulsive disorder in the National Comorbidity Survey Replication. *Molecular*
560 *Psychiatry*. 2010;15(1):53-63.
- 561 2. Grabe HJ, Meyer C, Hapke U, et al. Prevalence, quality of life and psychosocial
562 function in obsessive-compulsive disorder and subclinical obsessive-compulsive
563 disorder in northern Germany. *European Archives of Psychiatry and Clinical*
564 *Neuroscience*. 2000;250(5):262-268.
- 565 3. de Bruijn C, Beun S, de Graaf R, ten Have M, Denys D. Subthreshold symptoms and
566 obsessive-compulsive disorder: evaluating the diagnostic threshold. *Psychological*
567 *Medicine*. 2010;40(6):989-997.
- 568 4. *Diagnostic and statistical manual of mental disorders : DSM-5*. Arlington, VA:
569 American Psychiatric Association; 2013.
- 570 5. De Bruijn C, Beun S, De Graaf R, Ten Have M, Denys D. Subthreshold symptoms
571 and obsessive-compulsive disorder: Evaluating the diagnostic threshold.
572 *Psychological Medicine*. 2010;40(6):989-997.
- 573 6. Chamberlain SR, Leppink EW, Redden SA, Grant JE. Are obsessive-compulsive
574 symptoms impulsive, compulsive or both? *Comprehensive Psychiatry*. 2016;68:111-
575 118.
- 576 7. Ivarsson T, Melin K, Wallin L. Categorical and dimensional aspects of co-morbidity
577 in obsessive-compulsive disorder (OCD). *European Child & Adolescent Psychiatry*.
578 2008;17(1):20-31.
- 579 8. Clark LA, Cuthbert B, Lewis-Fernández R, Narrow WE, Reed GM. Three
580 Approaches to Understanding and Classifying Mental Disorder: ICD-11, DSM-5, and
581 the National Institute of Mental Health's Research Domain Criteria (RDoC).
582 *Psychological Science in the Public Interest*. 2017;18(2):72-145.
- 583 9. Fontenelle LF, Mendlowicz MV, Versiani M. The descriptive epidemiology of
584 obsessive-compulsive disorder. *Progress in Neuro-Psychopharmacology and*
585 *Biological Psychiatry*. 2006;30(3):327-337.
- 586 10. Hollander E, Kim S, Khanna S, Pallanti S. Obsessive-Compulsive Disorder and
587 Obsessive-Compulsive Spectrum Disorders: Diagnostic and Dimensional Issues. *CNS*
588 *Spectrums*. 2007;12(S3):5-13.
- 589 11. Boisseau CL, Thompson-Brenner H, Caldwell-Harris C, Pratt E, Farchione T,
590 Harrison Barlow D. Behavioral and cognitive impulsivity in obsessive-compulsive
591 disorder and eating disorders. *Psychiatry Research*. 2012;200(2):1062-1066.
- 592 12. Guo K, Youssef GJ, Dawson A, et al. A psychometric validation study of the
593 Impulsive-Compulsive Behaviours Checklist: A transdiagnostic tool for addictive and
594 compulsive behaviours. *Addictive Behaviors*. 2017;67:26-33.
- 595 13. Zermatten A, Van der Linden M. Impulsivity in non-clinical persons with obsessive-
596 compulsive symptoms. *Personality and Individual Differences*. 2008;44(8):1824-
597 1830.
- 598 14. Luigjes J, Lorenzetti V, de Haan S, et al. Defining Compulsive Behavior.
599 *Neuropsychology Review*. 2019;29(1):4-13.
- 600 15. Albertella L, Le Pelley ME, Chamberlain SR, et al. Reward-related attentional capture
601 is associated with severity of addictive and obsessive-compulsive behaviors.
602 *Psychology of Addictive Behaviors*. 2019;33(5):495-502.
- 603 16. Albertella L, Le Pelley ME, Chamberlain SR, et al. Reward-related attentional capture
604 and cognitive inflexibility interact to determine greater severity of compulsivity-

- 605 related problems. *Journal of Behavior Therapy and Experimental Psychiatry*.
 606 2020;69:101580.
- 607 17. Fullana MA, Mataix-Cols D, Caseras X, et al. High sensitivity to punishment and low
 608 impulsivity in obsessive-compulsive patients with hoarding symptoms. *Psychiatry*
 609 *Research*. 2004;129(1):21-27.
- 610 18. Grassi G, Pallanti S, Righi L, et al. Think twice: Impulsivity and decision making in
 611 obsessive-compulsive disorder. *Journal of Behavioral Addictions J Behav Addict*.
 612 2015;4(4):263-272.
- 613 19. Sohn SY, Kang JI, Namkoong K, Kim SJ. Multidimensional measures of impulsivity
 614 in obsessive-compulsive disorder: Cannot wait and stop. *PLoS ONE*. 2014;9(11).
- 615 20. Won Kim S, Grant JE. Personality dimensions in pathological gambling disorder and
 616 obsessive-compulsive disorder. *Psychiatry Research*. 2001;104(3):205-212.
- 617 21. Chamberlain SR, Stochl J, Redden SA, Grant JE. Latent traits of impulsivity and
 618 compulsivity: Toward dimensional psychiatry. *Psychological Medicine*.
 619 2018;48(5):810-821.
- 620 22. Fineberg NA, Chamberlain SR, Goudriaan AE, et al. New developments in human
 621 neurocognition: Clinical, genetic, and brain imaging correlates of impulsivity and
 622 compulsivity. *CNS Spectrums*. 2014;19(1):69-89.
- 623 23. Robbins TW, Gillan CM, Smith DG, de Wit S, Ersche KD. Neurocognitive
 624 endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry.
 625 *Trends in Cognitive Sciences*. 2012;16(1):81-91.
- 626 24. Fontenelle LF, Oostermeijer S, Harrison BJ, Pantelis C, Yücel M. Obsessive-
 627 Compulsive Disorder, Impulse Control Disorders and Drug Addiction. *Drugs*.
 628 2011;71(7):827-840.
- 629 25. Prochazkova L, Parkes L, Dawson A, et al. Unpacking the role of self-reported
 630 compulsivity and impulsivity in obsessive-compulsive disorder. *CNS Spectrums*.
 631 2018;23(1):51-58.
- 632 26. Kashyap H, Fontenelle LF, Miguel EC, et al. 'Impulsive compulsivity' in obsessive-
 633 compulsive disorder: A phenotypic marker of patients with poor clinical outcome.
 634 *Journal of Psychiatric Research*. 2012;46(9):1146-1152.
- 635 27. Yücel M, Lee RSC, Fontenelle LF. A New Consensus Framework for Phenotyping
 636 and Treatment Selecting in Addiction and Obsessive-Compulsive-Related Disorders.
 637 *JAMA Psychiatry*. 2021;78(7):699-700.
- 638 28. Smith JL, Mattick RP, Jamadar SD, Iredale JM. Deficits in behavioural inhibition in
 639 substance abuse and addiction: A meta-analysis. *Drug and Alcohol Dependence*.
 640 2014;145:1-33.
- 641 29. Chamberlain SR, Sahakian BJ. The neuropsychiatry of impulsivity. *Current Opinion*
 642 *in Psychiatry*. 2007;20(3).
- 643 30. Chamberlain SR, Fineberg NA, Menzies LA, et al. Impaired Cognitive Flexibility and
 644 Motor Inhibition in Unaffected First-Degree Relatives of Patients With Obsessive-
 645 Compulsive Disorder. *American Journal of Psychiatry*. 2007;164(2):335-338.
- 646 31. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The
 647 neuropsychology of obsessive compulsive disorder: the importance of failures in
 648 cognitive and behavioural inhibition as candidate endophenotypic markers.
 649 *Neuroscience & Biobehavioral Reviews*. 2005;29(3):399-419.
- 650 32. Endrass T, Schuermann B, Kaufmann C, Spielberg R, Kniesche R, Kathmann N.
 651 Performance monitoring and error significance in patients with obsessive-compulsive
 652 disorder. *Biological Psychology*. 2010;84(2):257-263.

- 653 33. Endrass T, Klawohn J, Schuster F, Kathmann N. Overactive performance monitoring
654 in obsessive-compulsive disorder: ERP evidence from correct and erroneous
655 reactions. *Neuropsychologia*. 2008;46(7):1877-1887.
- 656 34. Norman LJ, Taylor SF, Liu Y, et al. Error Processing and Inhibitory Control in
657 Obsessive-Compulsive Disorder: A Meta-analysis Using Statistical Parametric Maps.
658 *Biological Psychiatry*. 2019;85(9):713-725.
- 659 35. Ruchow M, Spitzer M, Grön G, Grothe J, Kiefer M. Error processing and
660 impulsiveness in normals: evidence from event-related potentials. *Cognitive Brain*
661 *Research*. 2005;24(2):317-325.
- 662 36. Gillan CM, Robbins TW, Sahakian BJ, van den Heuvel OA, van Wingen G. The role
663 of habit in compulsivity. *European Neuropsychopharmacology*. 2016;26(5):828-840.
- 664 37. Falkenstein M, Hoormann J, Hohnsbein J. ERP components in Go/Nogo tasks and
665 their relation to inhibition. *Acta Psychologica*. 1999;101(2):267-291.
- 666 38. Kim M-S, Kim YY, Yoo SY, Kwon JS. Electrophysiological correlates of behavioral
667 response inhibition in patients with obsessive-compulsive disorder. *Depression and*
668 *Anxiety*. 2007;24(1):22-31.
- 669 39. Wessel JR, Aron AR. It's not too late: The onset of the frontocentral P3 indexes
670 successful response inhibition in the stop-signal paradigm. *Psychophysiology*.
671 2015;52(4):472-480.
- 672 40. Ruchow M, Groen G, Kiefer M, et al. Response inhibition in borderline personality
673 disorder: Event-related potentials in a Go/Nogo task. *Journal of Neural Transmission*.
674 2008;115(1):127-133.
- 675 41. Ruchow M, Groen G, Kiefer M, Hermle L, Spitzer M, Falkenstein M. Impulsiveness
676 and ERP components in a Go/Nogo task. *Journal of Neural Transmission*.
677 2008;115(6):909-915.
- 678 42. Shen IH, Lee DS, Chen CL. The role of trait impulsivity in response inhibition:
679 Event-related potentials in a stop-signal task. *International Journal of*
680 *Psychophysiology*. 2014;91(2):80-87.
- 681 43. Kim M, Lee TH, Choi JS, et al. Neurophysiological correlates of altered response
682 inhibition in internet gaming disorder and obsessive-compulsive disorder:
683 Perspectives from impulsivity and compulsivity. *Scientific Reports*. 2017;7.
- 684 44. Perera MPN, Bailey NW, Herring SE, Fitzgerald PB. Electrophysiology of obsessive
685 compulsive disorder: A systematic review of the electroencephalographic literature.
686 *Journal of Anxiety Disorders*. 2019;62:1-14.
- 687 45. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive
688 Compulsive Scale: I. Development, Use, and Reliability. *Archives of General*
689 *Psychiatry*. 1989;46(11):1006-1011.
- 690 46. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International
691 Neuropsychiatric Interview (M.I.N.I.): The development and validation of a
692 structured diagnostic psychiatric interview for DSM-IV and ICD-10. *Journal of*
693 *Clinical Psychiatry*. 1998;59(SUPPL. 20):22-33.
- 694 47. Parkes L, Tiego J, Aquino K, et al. Transdiagnostic variations in impulsivity and
695 compulsivity in obsessive-compulsive disorder and gambling disorder correlate with
696 effective connectivity in cortical-striatal-thalamic-cortical circuits. *NeuroImage*.
697 2019;202:116070.
- 698 48. Tiego J, Oostermeijer S, Prochazkova L, et al. Overlapping dimensional phenotypes
699 of impulsivity and compulsivity explain co-occurrence of addictive and related
700 behaviors. *CNS Spectrums*. 2019;24(4):426-440.
- 701 49. Tiego J, Chamberlain SR, Harrison BJ, et al. Heritability of overlapping impulsivity
702 and compulsivity dimensional phenotypes. *Scientific Reports*. 2020;10(1).


- 703 50. Moulding R, Anglim J, Nedeljkovic M, Doron G, Kyrios M, Ayalon A. The
704 Obsessive Beliefs Questionnaire (OBQ): Examination in Nonclinical Samples and
705 Development of a Short Version. *Assessment*. 2010;18(3):357-374.
- 706 51. Buhr K, Dugas MJ. The intolerance of uncertainty scale: psychometric properties of
707 the English version. *Behaviour Research and Therapy*. 2002;40(8):931-945.
- 708 52. Cyders MA, Littlefield AK, Coffey S, Karyadi KA. Examination of a short English
709 version of the UPPS-P Impulsive Behavior Scale. *Addictive Behaviors*.
710 2014;39(9):1372-1376.
- 711 53. Tennant R, Hiller L, Fishwick R, et al. The Warwick-Edinburgh Mental Well-being
712 Scale (WEMWBS): development and UK validation. *Health and Quality of Life
713 Outcomes*. 2007;5(1):63.
- 714 54. Bass M, Dawkin M, Muncer S, Vigurs S, Bostock J. Validation of Warwick-
715 Edinburgh Mental Well-being Scale (WEMWBS) in a population of people using
716 Secondary Care Mental Health Services. *Journal of Mental Health*. 2016;25(4):323-
717 329.
- 718 55. Verbruggen F, Logan GD. Response inhibition in the stop-signal paradigm. *Trends in
719 cognitive sciences*. 2008;12(11):418-424.
- 720 56. Verbruggen F, Aron AR, Band GPH, et al. A consensus guide to capturing the ability
721 to inhibit actions and impulsive behaviors in the stop-signal task. *eLife*.
722 2019;8:e46323.
- 723 57. Delorme A, Makeig S. EEGLAB: An open source toolbox for analysis of single-trial
724 EEG dynamics including independent component analysis. *Journal of Neuroscience
725 Methods*. 2004;134(1):9-21.
- 726 58. Dimoska A, Johnstone SJ, Barry RJ. The auditory-evoked N2 and P3 components in
727 the stop-signal task: Indices of inhibition, response-conflict or error-detection? *Brain
728 and Cognition*. 2006;62(2):98-112.
- 729 59. Hajcak G, Moser JS, Yeung N, Simons RF. On the ERN and the significance of
730 errors. *Psychophysiology*. 2005;42(2):151-160.
- 731 60. Ramautar JR, Kok A, Ridderinkhof KR. Effects of stop-signal probability in the stop-
732 signal paradigm: The N2/P3 complex further validated. *Brain and Cognition*.
733 2004;56(2 SPEC. ISS.):234-252.
- 734 61. Imburgio MJ, Banica I, Hill KE, Weinberg A, Foti D, MacNamara A. Establishing
735 norms for error-related brain activity during the arrow Flanker task among young
736 adults. *NeuroImage*. 2020;213:116694.
- 737 62. Albertella L, Rotaru K, Christensen E, et al. The Influence of Trait Compulsivity and
738 Impulsivity on Addictive and Compulsive Behaviors During COVID-19. *Frontiers in
739 Psychiatry*. 2021;12:162.
- 740 63. Williams BR, Ponesse JS, Schachar RJ, Logan GD, Tannock R. Development of
741 inhibitory control across the life span. *Developmental psychology*. 1999;35(1):205-
742 213.
- 743 64. Kim M, Lee TH, Choi J-S, et al. Neurophysiological correlates of altered response
744 inhibition in internet gaming disorder and obsessive-compulsive disorder:
745 Perspectives from impulsivity and compulsivity. *Scientific reports*. 2017;7:41742-
746 41742.
- 747 65. Bekker EM, Kenemans JL, Verbaten MN. Source analysis of the N2 in a cued
748 Go/NoGo task. *Cognitive Brain Research*. 2005;22(2):221-231.
- 749 66. Bokura H, Yamaguchi S, Kobayashi S. Electrophysiological correlates for response
750 inhibition in a Go/NoGo task. *Clinical Neurophysiology*. 2001;112(12):2224-2232.

- 751 67. Swainson R, Cunnington R, Jackson GM, et al. Cognitive Control Mechanisms
752 Revealed by ERP and fMRI: Evidence from Repeated Task-Switching. *Journal of*
753 *Cognitive Neuroscience*. 2003;15(6):785-799.
- 754 68. Aron AR, Poldrack RA. Cortical and Subcortical Contributions to Stop Signal
755 Response Inhibition: Role of the Subthalamic Nucleus. *The Journal of Neuroscience*.
756 2006;26(9):2424.
- 757 69. Lubman DI, Yücel M, Pantelis C. Addiction, a condition of compulsive behaviour?
758 Neuroimaging and neuropsychological evidence of inhibitory dysregulation.
759 *Addiction*. 2004;99(12):1491-1502.
- 760 70. Lei H, Zhu X, Fan J, et al. Is impaired response inhibition independent of symptom
761 dimensions in obsessive-compulsive disorder? Evidence from ERPs. *Scientific*
762 *Reports*. 2015;5(1):10413.
- 763 71. Tiego J, Chamberlain SR, Harrison BJ, et al. Heritability of overlapping impulsivity
764 and compulsivity dimensional phenotypes. *Scientific Reports*. 2020;10(1):14378.
- 765 72. Kok A, Ramautar JR, De Ruiter MB, Band GPH, Ridderinkhof KR. ERP components
766 associated with successful and unsuccessful stopping in a stop-signal task.
767 *Psychophysiology*. 2004;41(1):9-20.
- 768 73. Harmon-Jones E, Barratt ES, Wigg C. Impulsiveness, aggression, reading, and the
769 P300 of the event-related potential. *Personality and Individual Differences*.
770 1997;22(4):439-445.
- 771 74. Herrmann MJ, Jacob C, Unterecker S, Fallgatter AJ. Reduced response-inhibition in
772 obsessive-compulsive disorder measured with topographic evoked potential mapping.
773 *Psychiatry Research*. 2003;120(3):265-271.
- 774 75. Moeller FG, Barratt ES, Fischer CJ, et al. P300 Event-Related Potential Amplitude
775 and Impulsivity in Cocaine-Dependent Subjects. *Neuropsychobiology*.
776 2004;50(2):167-173.
- 777 76. Fitzgerald KD, Welsh RC, Gehring WJ, et al. Error-related hyperactivity of the
778 anterior cingulate cortex in obsessive-compulsive disorder. *Biological Psychiatry*.
779 2005;57(3):287-294.
- 780 77. van Boxtel GJM, van der Molen MW, Jennings JR. Differential Involvement of the
781 Anterior Cingulate Cortex in Performance Monitoring During a Stop-Signal Task.
782 *Journal of Psychophysiology*. 2005;19(1):1-10.
- 783 78. Hajcak G, Simons RF. Error-related brain activity in obsessive-compulsive
784 undergraduates. *Psychiatry Research*. 2002;110(1):63-72.
- 785 79. McLaughlin NCR, Kirschner J, Foster H, O'Connell C, Rasmussen SA, Greenberg
786 BD. Stop Signal Reaction Time Deficits in a Lifetime Obsessive-Compulsive
787 Disorder Sample. *Journal of the International Neuropsychological Society*.
788 2016;22(7):785-789.
- 789 80. Dhir S, Teo W-P, Chamberlain SR, Tyler K, Yücel M, Segrave RA. The Effects of
790 Combined Physical and Cognitive Training on Inhibitory Control: A Systematic
791 Review and Meta-Analysis. *Neuroscience & Biobehavioral Reviews*. 2021;128:735-
792 748.
- 793 81. Gajewski PD, Falkenstein M. Effects of task complexity on ERP components in
794 Go/Nogo tasks. *International Journal of Psychophysiology*. 2013;87(3):273-278.
- 795 82. Maguire MJ, Brier MR, Moore PS, et al. The influence of perceptual and semantic
796 categorization on inhibitory processing as measured by the N2-P3 response. *Brain*
797 *and Cognition*. 2009;71(3):196-203.
- 798 83. Smith JL, Johnstone SJ, Barry RJ. Movement-related potentials in the Go/NoGo task:
799 The P3 reflects both cognitive and motor inhibition. *Clinical Neurophysiology*.
800 2008;119(3):704-714.

- 801 84. Waller DA, Hazeltine E, Wessel JR. Common neural processes during action-
802 stopping and infrequent stimulus detection: The frontocentral P3 as an index of
803 generic motor inhibition. *International Journal of Psychophysiology*. 2021;163:11-21.
804 85. Carlson SR, Thái S, McLarnon ME. Visual P3 amplitude and self-reported
805 psychopathic personality traits: Frontal reduction is associated with self-centered
806 impulsivity. *Psychophysiology*. 2009;46(1):100-113.
807 86. Kopp B, Mattler U, Goertz R, Rist F. N2, P3 and the lateralized readiness potential in
808 a nogo task involving selective response priming. *Electroencephalography and*
809 *Clinical Neurophysiology*. 1996;99(1):19-27.
810

811

Figures and Tables

812 **Figure 1:** Schematic Representation of N2, P3 and ERN/CRN during The Stop Signal Task

813

814 Abbreviation: Ms, Milliseconds. μ V, Microvolts. SSRT, Stop Signal Reaction Time.


815 Note. During the Stop Signal Task, participants are required to respond via button press (left
 816 or right arrow) to a Go signal (grey arrows), however in some cases the Go signal is followed
 817 by a 'Stop Signal' (red arrow) and they are required withhold the initiated urge to respond.
 818 The SSRT measures the time from the stop signal to the inhibition response, thus indicates
 819 inhibition speed. Discrete neurocognitive components of the inhibitory control process are
 820 reflected in ERPs, as follow: N2 amplitude = pre-conscious awareness of the need to stop, P3
 821 onset latency = onset of the inhibition process, P3 amplitude = the magnitude of inhibition
 822 response, CRN = monitoring of successful inhibition, and ERN = monitoring of failed
 823 inhibition.

824 **Table 1:** Participant Characteristics Across Variables and Normative Data for SSRT, P3 Onset, ERN/CRN and Well-Being

| Variable | Normative Comparison | Mean | SD |
|--------------------------------|--|---|---|
| Impulsivity | N/A | 11.03 | 2.12 |
| Compulsivity | N/A | 106.72 | 21.61 |
| YBOCS | Mild = 1-15 Moderate = 16 - 23 | 15.75 | 5.12 |
| WEMWBS | Healthy Young Adults Median: 51, 95% CI 50 – 53 People Accessing Secondary Care Mental Health Service Mean (SD): = 34.9 (13.8) | Median: Mild: 28.5 Moderate: 37 Mean: Mild: 31 Moderate: 35.55 | 95% CI: Mild: 26.61 – 35.38 Moderate: 30.76 – 40.33 SD: Mild: 8.81 Moderate: 10.79 |
| SSRT (<i>ms</i>) | 208.6 (SD = 75.1) | 215.72 | 31.35 |
| N2 Amplitude (μV) | | | |
| Failed Stop Trials | N/A | -.68 | 1.09 |
| Successful Stop Trials | N/A | -.52 | .99 |
| P3 Onset Latency (<i>ms</i>) | | | |
| Failed Stop Trials | 259.9 (SE = 6) | 303.58 | 37.95 |
| Successful Stop Trials | 225.2 (SE = 4.5) | 257.50 | 43.16 |
| P3 Amplitude (μV) | | | |
| Failed Stop Trials | N/A | 1.90 | 2.09 |
| Successful Stop Trials | N/A | 2.22 | 2.29 |
| ERN (μV) | 3.27 (SD = 6.56) | -.21 | 1.91 |
| CRN (μV) | 9.02 (SD = 5.29) | -.32 | .75 |

825 Abbreviation: M, Means. SD, Standard Deviations. SE, Standard Error. Ms, Milliseconds. μV , Microvolts.


826 Note. There are not reliable normative data for N2 and P3 amplitudes during the SST.

827 **Figure 2:** Grand Average of The N2 from the Cz Electrode and The P3 from the Fz Electrode

828

829 Abbreviation: μV , Microvolts. Ms, Millisecond. FS, = Failed stop trials during the SST (i.e.,
 830 red arrow presented at 0ms and participants incorrectly responded). SS, = Successful stop
 831 trials during the SST (red arrow presented at 0ms and participants correctly withheld a
 832 response). GO, = Go trials during the SST (white arrow presented at 0ms and participants
 833 responded).

834

835 **Figure 3:** Grand Average of The ERN and CRN from the Cz Electrode

836


837 Abbreviation: μV , Microvolts. Ms, Millisecond. ERN, Error Related Negativity. CRN,
838 Correct Related Negativity.

839 Note: Response ('correct' response - withholding a response to the 'stop signal', 'incorrect'
840 response - responding to the 'stop signal') occurred at 0ms, shaded area corresponds to the 0-
841 100ms period in which negativity was calculated. ERN and CRN index negativity after
842 incorrect and correct responses, respectively.

843

844

845 **Figure 4:** N2 Amplitude During Failed Stop Trials as a Function of Compulsivity Across
 846 Low and High Impulsivity



847

848 Abbreviation: µV, Microvolts. UPPS-P, Urgency, Premeditation (lack of), Perseverance (lack


849 of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale. OBQ, Obsessional

850 Beliefs Questionnaire. IUS, Intolerance of Uncertainty Scale

851

852

853 **Figure 5:** P3 Onset During Successful Stop Trials as a Function of Impulsivity




854

855 Abbreviation: μ V, Microvolts. UPPS-P, Urgency, Premeditation (lack of), Perseverance (lack
856 of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale.

857

858

859 **Figure 6:** P3 Amplitude During Failed Stop Trials as a Function of Compulsivity Across
 860 Low and High Impulsivity




861

862 Abbreviation: µV, Microvolts. UPPS-P, Urgency, Premeditation (lack of), Perseverance (lack
 863 of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale. OBQ, Obsessional
 864 Beliefs Questionnaire. IUS, Intolerance of Uncertainty Scale.

865 Note. Significant correlation between compulsivity and P3 amplitude in low impulsivity ($r =$
 866 $-.544, p < .05$). Microvolts (µV). UPPS-P = Urgency, Premeditation (lack of), Perseverance
 867 (lack of), Sensation Seeking, Positive Urgency, Impulsive Behavior Scale. OBQ =
 868 Obsessional Beliefs Questionnaire. IUS = Intolerance of Uncertainty Scale.

869

870 **Figure 7: CRN as a Function of Compulsivity**

871

872 Abbreviation: μV , Microvolts. OBQ, Obsessional Beliefs Questionnaire. IUS, Intolerance of
 873 Uncertainty Scale.

874 *Note.* Trait compulsivity was associated with larger CRN ($p < .05$). *Microvolts (μV)*. OBQ =
 875 Obsessional Beliefs Questionnaire. IUS = Intolerance of Uncertainty Scale.